Notice of Annual General Meeting of Brain+ A/S and Change to the Board of Directors
Invitation to Annual General Meeting The shareholders of Brain+ A/S are hereby invited to attend the Annual General Meeting scheduled for 18th May 2022, 14:00. The general meeting will be take place at Hauser Pl. 20, 5., 1127 København as a physical event.
Summary from Annual Report 2021: Brain+ (BRAINP) is ahead of its IPO plan
“We are dedicated to helping people with dementia and Alzheimer’s disease – their families and their caregivers – through the use of our unique Digital Therapeutic software solutions that are being developed and validated through rigorous scientific and clinical trials. 2021 brought us closer to this core objective and we are now in a strong position to launch our first dementia product in 2023, 2 years ahead of plan. This will be a highly important commercial first step towards leadership in an emerging US billion-dollar market”, said Kim Baden-Kristensen, CEO of Brain+.
Annual Report 2021 for Brain+ A/S
Brain+ annual report for 2021 is now available on the Company´s website
Brain+ CTO unfolds the Company’s Technology Platform Strategy
Paula Petcu joined Brain+ as new Chief Technology Officer after the company’s IPO in 2021, and is now driving forth the company’s product development work and technology platform initiatives. She came from Lundbeck A/S, a pioneering pharma company within central nervous system (CNS) disorders, where she built up the digital health organization. In this article, she explains the Brain+ platform strategy and technology stack. Summary highlights · Platform strategy: We are building a technology platform that is both modular, scalable, configurable, and regulatory compliant, while also allowing for high-quality data collection and easy integration with other apps and platforms. · Technology Stack: Our therapeutic software solutions are developed for both web and mobile applications using Flutter, which is a worldwide recognized framework for building multi-platform applications from a single codebase. We build on a German-based cloud infrastructure to ensure compliance with German and European data privacy requirements. And we use a microservices architecture for the flexibility and modularity of our products.
Brain+ selected as ‘digital showcase for Denmark’ by Digital Hub Denmark
Brain+ has been selected as showcase in the HealthTech category, among other top cutting-edge start-ups from Denmark, who are leading the digital transformation of society. The selection of Brain+ is motivated by the company’s achievements and commitment to make effective dementia and Alzheimer’s treatments available to everyone, as digital medicine.
The Danish Foreign Ministry to promote Brain+ into elderly care homes in Germany – Europe’s largest Alzheimer’s market
Brain+ has been identified by the Danish Foreign Ministry as a high potential Danish medtech company relevant for the German market. Therefore, Brain+ has been invited into the Danish-German Care Alliance (Dänisch-Deutsche Pflegeallianz), which aims to put Danish medical technologies directly into the hands of relevant large German customers. In practice, this means that Brain+ will get the opportunity to engage in a structured series of workshops with six large care home chains during 2022 with the aim of establishing local pilots and lead customers for the product launch in 2023.
Brain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeutics
Brain+ has been selected to Biogen’s and EIT Health’s exclusive Neurotech-prize program. This will give additional momentum to the preparations for launch of Brain+’s first dementia product on the German market in 2023. The German market is a global ‘reference’ market for Digital Therapeutics (DTx) products and succeeding here creates a strong base for global expansion.
Publication of results from an earlier study that showed cognitive improvements in people with Brain Injury after training with Brain+ Recover Computerized Cognitive Training product
BRAIN+ A/S Investor update · Critical, early validation of Brain+ Computerized Cognitive Training technology as effective on specific cognitive outcomes relevant for patients with dementia · Cognitive problems are primary symptoms in pre-stages of dementia and often caused by Alzheimer’s disease · Insights from this study have been built into both the design of Brain+’ new dementia product, Cognitive Stimulation Therapy, and the next generation of cognitive training Brain+ is devoloping to target pre-stages of dementia in Alzheimer’s patients
Known data from a pilot study that tested an early version the Brain+ Computerized Cognitive Training technology in Parkinson’s Disease has been published
BRAIN+ A/S Investor update · Feasibility of use by Parkinson’s patients was shown · Valuable information gained about patient compliance that is relevant for the products Brain+ is developing for Alzheimer’s and dementia · Insights from the study have been built into the Computerized Cognitive Training technology, which is currently being tested in people at risk of dementia, and from which results are expected later this year
Positive results from the first of four clinical studies to evaluate Brain+’ Starry Night cognitive test for early detection of Alzheimer’s Disease
BRAIN+ A/S (BRAINP) Company Announcement No. 2-2022 Thursday, February 3., 2022, 09:00 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014
Brain+ A/S (BRAINP) appoints Chief Financial Officer
BRAIN+ A/S (BRAINP) Company Announcement No. [1-2022] [Thursday January 27, 2022, 17:00 CET]
Year End Update on Business Activities and Outlook
BRAIN+ A/S (BRAINP) Wednesday, December 29, 2021, 9:00 CET Investor update
Brain+ lands first large-pharma partnership deal to enter the German market for dementia products
BRAIN+ A/S (BRAINP) Company Announcement No. 4-2021 Wednesday, December 15, 2021, 8:20 CET The information communicated in this announcement is “inside information” for the purposes of article 7 of the Market Abuse Regulation 596/2014 Brain+ has signed a partnership agreement with RoX Health (https://roxhealth.com/), a subsidiary of the global pharma company Roche in Germany, to bring its first dementia products to the German market.
2 months after IPO update
BRAIN+ A/S (BRAINP) Monday, December 13, 2021, 9:30 CET
Board member announces intention to leave board
BRAIN+ A/S (BRAINP) Company Announcement No. 3-2021 Tuesday November 16, 2021, 22:05 CET
Brain+ IPO 169% subscribed by 1,288 investors
The total subscription in the IPO was DKK 25.4 million from a total of 1,288 subscribers, translating into a subscription percentage of 169% counting all shares offered in the offering.
Danish Digital Medicine Company Brain+ Goes Public
THURSDAY, SEP 16, 2021 Brain+ A/S is offering Units and has applied for admission to trading on Nasdaq First North Growth Market Denmark.